Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 14/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17487341 | 0.88 | DRD2 (0.46) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17488099 | 0.88 | P2RX3 (0.46) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17487667 | 0.82 | DRD2 (0.43) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17487355 | 0.82 | SMN1; SMN2 (0.44) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17487335 | 0.81 | KDM4E (0.46) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17488303 | 0.77 | SOS1 (0.43) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17487459 | 0.77 | SOS1 (0.41) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17488001 | 0.77 | SMN1; SMN2 (0.41) | P2RX3DRD2TBXA2RKDM4EALDH1A1 | |
| SCHEMBL17487315 | 0.76 | SOS1 (0.59) | KDM4EALDH1A1NOD2SMN1; SMN2NOD1 | |
| SCHEMBL17488121 | 0.76 | SMN1; SMN2 (0.44) | P2RX3DRD2TBXA2RKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | P2RX3 750/4885DRD2 2624/4885TBXA2R 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.